Article open access publication

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

British Journal of Cancer, Springer Nature, ISSN 0007-0920

Volume 118, 2, 2018

DOI:10.1038/bjc.2017.429, Dimensions: pub.1100167394, PMC: PMC5785754, PMID: 29301143,

Authors

Dias, Alexander (1) (3)
Eccles, Diana (10) (11)
Lam, Jimmy (18)
Teixeira, Manuel R (27) (28)
Lindeman, Geoffrey J (8) (39) (40)
Kirk, Judy (44) (45)
Pachter, Nicholas (49) (50)
Spigelman, Allan (51) (52) (53)
Side, Lucy (54)
Brewer, Carole (57) (58)
Barwell, Julian (65) (66)
James, Paul A (8) (9) (40)
Friedman, Eitan (67) (68)
Kast, Karin (76) (77) (78)
Hamdy, Freddie C (36) (84)
Moss, Sue (88)
Lilja, Hans (4) (84)
Eeles, Rosalind A * (1) (3)

* Corresponding author

Affiliations

Organisations

  1. (1) Institute of Cancer Research, grid.18886.3f
  2. (2) NorthShore University HealthSystem, grid.240372.0
  3. (3) Royal Marsden NHS Foundation Trust, grid.5072.0
  4. (4) Memorial Sloan Kettering Cancer Center, grid.51462.34
  5. (5) University of Manchester, grid.5379.8
  6. (6) Oslo University Hospital, grid.55325.34
  7. (7) Akershus University Hospital, grid.411279.8
  8. (8) University of Melbourne, grid.1008.9
  9. (9) Peter MacCallum Cancer Centre, grid.1055.1
  10. (10) Cancer Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK
  11. (11) Princess Anne Hospital, grid.415216.5
  12. (12) Vejle Sygehus, grid.417271.6, Southern Denmark Region
  13. (13) Leiden University Medical Center, grid.10419.3d
  14. (14) Netherlands Foundation for the Detection of Hereditary Tumors, 2333, Leiden, ZA, The Netherlands
  15. (15) Radboud University Nijmegen Medical Centre, grid.10417.33
  16. (16) Pomeranian Medical University, grid.107950.a
  17. (17) Birmingham Women's Hospital, grid.423077.5
  18. (18) Department of Urology, Repatriation General Hospital, 5041, Daw Park, SA, Australia
  19. (19) Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L’Hospitalet de Llobregat, 08908, Barcelona, Spain
  20. (20) Erasmus University Medical Center, grid.5645.2
  21. (21) Department of Genetics, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands
  22. (22) Sheffield Children's Hospital, grid.413991.7
  23. (23) Royal Hallamshire Hospital, grid.416126.6
  24. (24) Huntsman Cancer Institute, grid.479969.c
  25. (25) University of Pennsylvania, grid.25879.31
  26. (26) University Medical Center Utrecht, grid.7692.a
  27. (27) University of Porto, grid.5808.5
  28. (28) Portuguese Oncology Institute, grid.418711.a
  29. (29) Guy's Hospital, grid.239826.4
  30. (30) University Hospital Cologne, grid.411097.a
  31. (31) McGill University, grid.14709.3b
  32. (32) Duncan Guthrie Institute of Medical Genetics, Yorkhill NHS Trust, G38SJ, Glasgow, UK
  33. (33) Antoni van Leeuwenhoek Hospital, grid.430814.a
  34. (34) Maastricht University Medical Centre, grid.412966.e
  35. (35) Prince of Wales Hospital, grid.415193.b
  36. (36) Churchill Hospital, grid.415719.f
  37. (37) St George's Hospital, grid.464688.0
  38. (38) Newcastle upon Tyne Hospitals NHS Foundation Trust, grid.420004.2
  39. (39) Walter and Eliza Hall Institute of Medical Research, grid.1042.7
  40. (40) Royal Melbourne Hospital, grid.416153.4
  41. (41) Karolinska University Hospital and Karolinska Institutet, 171 77, Solna, Sweden
  42. (42) Monash Health, grid.419789.a
  43. (43) VU University Medical Center, grid.16872.3a
  44. (44) Centre for Cancer Research, The Westmead Institute for Medical Research, Westmead, 2155, Sydney, NSW, Australia
  45. (45) Westmead Hospital, grid.413252.3
  46. (46) Cambridge University Hospitals NHS Foundation Trust, grid.24029.3d
  47. (47) Royal Brisbane and Women's Hospital, grid.416100.2
  48. (48) Kaplan Medical Center, grid.415014.5
  49. (49) King Edward Memorial Hospital, grid.415259.e
  50. (50) University of Western Australia, grid.1012.2
  51. (51) Hunter Family Cancer Service, 2298, Waratah, NSW, Australia
  52. (52) The Kinghorn Cancer Centre, grid.410697.d
  53. (53) UNSW Sydney, grid.1005.4
  54. (54) NE Thames Regional Genetics Service, Great Ormond St Hospital & UCL Institute of Women’s Health, WC1N 3JH, London, UK
  55. (55) Institute of Oncology Ljubljana, grid.418872.0
  56. (56) Hospital de Sant Pau, grid.413396.a
  57. (57) Derriford Hospital, grid.413628.a
  58. (58) Royal Devon and Exeter Hospital, grid.416118.b
  59. (59) Hospital Universitari Vall d'Hebron, grid.411083.f
  60. (60) London North West Healthcare NHS Trust, grid.439803.5
  61. (61) St. James's Hospital, grid.416409.e
  62. (62) Academic Medical Center, grid.5650.6
  63. (63) St Michael's Hospital, grid.416544.6
  64. (64) National University Hospital of Iceland, grid.410540.4
  65. (65) University Hospitals of Leicester NHS Trust, grid.269014.8
  66. (66) University of Leicester, grid.9918.9
  67. (67) Sheba Medical Center, grid.413795.d
  68. (68) Tel Aviv University, grid.12136.37
  69. (69) Fondazione IRCCS Istituto Nazionale dei Tumori, grid.417893.0
  70. (70) Liverpool Women's Hospital, grid.415996.6
  71. (71) Temple University Health System, grid.412530.1
  72. (72) Tata Memorial Hospital, grid.410871.b
  73. (73) Národný Onkologický Ustav, grid.419188.d
  74. (74) Cancer Research Initiatives Foundation, Subang Jaya Medical Centre, 47500, Subang Jaya, Selangor, Darul Ehsan, Malaysia
  75. (75) The University of Texas MD Anderson Cancer Center, grid.240145.6
  76. (76) German Cancer Research Center, grid.7497.d
  77. (77) TU Dresden, grid.4488.0
  78. (78) University Hospital Heidelberg, grid.5253.1
  79. (79) Spanish National Cancer Research Centre, grid.7719.8
  80. (80) University of Iceland, grid.14013.37
  81. (81) Imperial College Healthcare NHS Trust, grid.417895.6
  82. (82) Homes England, grid.420746.3
  83. (83) University Hospital of Umeå, grid.412215.1
  84. (84) University of Oxford, grid.4991.5
  85. (85) University College London Hospitals NHS Foundation Trust, grid.52996.31
  86. (86) Carmel Medical Center, grid.413469.d
  87. (87) Nottingham City Hospital, grid.412920.c
  88. (88) Queen Mary University of London, grid.4868.2

Description

BACKGROUND: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort. METHODS: PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB) in men with elevated PSA values. Cox regression was used to determine whether PSA or PSAV predicted PSA elevation in men with low PSAs. Interaction terms were included in the models to determine whether BRCA status influenced the predictiveness of PSA or PSAV. RESULTS: 1634 participants had ⩾3 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed. In men with PSA >3.0 ng ml-l, PSAV was not significantly associated with presence of cancer or high-grade disease. PSAV did not add to PSA for predicting time to an elevated PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction between BRCA status and last PSA before biopsy (P=0.031) and BRCA2 status and PSAV (P=0.024). However, PSAV was not predictive of biopsy outcome in BRCA2 carriers. CONCLUSIONS: PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We did not find evidence that PSAV aids decision-making for BRCA carriers over absolute PSA value alone.

Funders

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

University of Southern Denmark

Danish Open Access Indicator

2018: Realized

Research area: Medicine

Danish Bibliometrics Indicator

2018: Level 1

Research area: Medicine

Dimensions Citation Indicators

Times Cited: 9

Field Citation Ratio (FCR): 5.54

Relative Citation ratio (RCR): 0.26

Open Access Info

Hybrid